Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Wang, L., Martin, P., Blum, K. A., Kahl, B. S., Maeda, L. S., Advani, R., Williams, M. E., Rule, S., Rodriguez, S., Pang, C., Hedrick, E., Goy, A. AMER SOC HEMATOLOGY. 2011: 203–4
View details for Web of Science ID 000299597100443